Jonathan Ejie | Personalized Medicine | Best Research Article Award

Published on by Top Pharmaceutical

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Mr. Jonathan Ejie, UCSF, United States

Mr. Jonathan Ejie is an aspiring physician-scientist currently pursuing his M.D. at UCSF 🩺 (Class of 2026), following a B.S. in Electrical Engineering & Computer Science from UC Berkeley 💻. His research spans oncology, radiology, and AI in healthcare, with published work in Cancers (2025) and upcoming studies in Nature Communications 📊. Jonathan integrates data science 🧠 with clinical insights, contributing to health equity, quality improvement, and surgical education. A mentor, tutor, and award-winning leader 🏅, he co-founded the UCSF Futbol Club and serves underserved communities through advocacy and outreach.

Publication Profile 

Orcid

Education

Mr. Jonathan Ejie is an exceptional scholar whose educational journey bridges medicine and technology. He is currently pursuing his Doctor of Medicine (M.D.) degree at the prestigious University of California, San Francisco (UCSF) 🏥, with an expected graduation in 2026. Prior to this, he earned a Bachelor of Science in Electrical Engineering and Computer Science (EECS) 💻 from the University of California, Berkeley, graduating in 2022. His strong foundation in both engineering and clinical science equips him with a unique interdisciplinary perspective 🤖🩺, positioning him at the forefront of innovation in digital health and precision medicine.

Experience

Mr. Jonathan Ejie brings a blend of academic support and compassionate service to his professional journey. As an MCAT Physics Tutor at UCSF (2023), he guided 15+ students through complex physics concepts 📘⚛️. Earlier, at Contra Costa College (2019–2021), he tutored mathematics from Algebra to Calculus ➕📐. His volunteer work includes providing first aid at athletic events 🏃‍♂️🩹, teaching surgical skills to high school students at UCSF 🧵🧑‍⚕️, and serving as a Health Advocate at West County Health Center 💬🩺, helping underserved patients access vital community resources. His dedication reflects a strong commitment to both education and public health.

Awards

Mr. Jonathan Ejie has been recognized for his academic excellence and impactful contributions to medicine and research. In 2024, he was honored with the prestigious Sinkler Miller Medical Association Scholarship 🎖️, sponsored by Gilead, celebrating his commitment to health equity and academic distinction. He also received the UCSF School of Medicine Summer Explore Fellowship Grant 🌟, supporting his innovative pursuits in medical research. In May 2023, Jonathan earned the Inquiry Conference Travel and Dissemination Award ✈️📊, which enabled him to share his scholarly findings on a larger stage. These accolades reflect his rising potential and leadership in healthcare.

Research Focus 

Mr. Jonathan Ejie’s research focus lies at the intersection of oncology, health disparities, and medical data science. His standout work on the “Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer” 📉🩺 highlights critical inequities in healthcare delivery across race, geography, and insurance status. Combining his background in medicine 🧑‍⚕️ and computer science 💻, Jonathan leverages data analysis and machine learning 🤖📊 to drive systemic improvements in cancer care. His work reflects a commitment to equity, evidence-based medicine, and the pursuit of personalized, accessible treatment strategies for vulnerable cancer populations.

Publication Top Notes

  • Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer

Jian Shi | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Jian Shi | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Jian Shi, Neurology of UCSF, United States

Assoc. Prof. Dr. Jian Shi is a distinguished neuroscientist at the University of California, San Francisco, with a Ph.D. in Neurobiology from Navy Medical University, China. 🧬 He completed postdoctoral training at the University of Texas Southwestern Medical Center, focusing on neuroscience. His research integrates brain injury, neurodegenerative diseases, and glioblastoma with cutting-edge AI and bioinformatics tools. 🧪🧠 Dr. Shi has authored highly cited publications and received numerous accolades, including the APS Outstanding Paper Award. 🌟 A dedicated mentor and educator, he actively contributes to diversity and public service in neurology and biomedical research.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Jian Shi began his academic journey at the National University of Defense Technology in Hunan Province, China, earning both his B.S. and M.S. degrees in Biomechanics. ⚙️📘 He then pursued his Ph.D. in Neurobiology under the mentorship of Dr. Lu Changlin at the prestigious Navy Medical University in Shanghai. 🧬🏥 Driven by a passion for neuroscience, he completed his postdoctoral training at the University of Texas Southwestern Medical Center under the guidance of Dr. Steven G. Kernie, focusing on advanced neuroscience research. 🧠🔬 His academic foundation bridges biomechanics and cutting-edge neurobiological science.

Awards

Assoc. Prof. Dr. Jian Shi has received numerous accolades recognizing his excellence in research and education. 🇨🇳 He was honored with the prestigious National Award for Scientific Progress, Level 2 in China 🥇🔬 and received the Award for Outstanding Scientists from Navy Medical University, where he also earned the Best Teacher Award for his commitment to academic excellence 👨‍🏫🌟. His groundbreaking work earned him the “Top 50 Most Cited Article Award” from the Journal of Clinical Medicine 📖📈 and the APS Outstanding Paper Award from Acta Pharmacologica Sinica 🧪🏅. He is also recognized as a Trusted Reviewer by the International Journal of Molecular Sciences 🧠✅.

Research Focus

Assoc. Prof. Dr. Jian Shi’s research centers around neurobiology, with a strong emphasis on traumatic brain injury (TBI) 🧠💥, neurodegeneration 🧬, neurogenesis 🌱, and molecular neuroscience. His work explores small molecule therapies, microglial activation, intranasal drug delivery 💊, and microRNA biomarkers, particularly in the context of glioblastoma and stroke. He also investigates brain repair mechanisms, exosomal signaling 📦, and neurotrophin-mimetic compounds. In recent years, his interdisciplinary work has extended to climate impact models 🌍 and machine learning applications 🤖 in brain science, reflecting a comprehensive and innovative research portfolio in translational neuroscience and brain health.

Publication Top Notes

Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents

Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor

Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia

Considering exosomal miR-21 as a biomarker for cancer

The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury

A small molecule p75NTR ligand protects neurogenesis after traumatic brain injury

MicroRNAs as biomarkers for human glioblastoma: progress and potential

Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers

Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental …

Beneficial effects of minocycline and botulinum toxin–induced constraint physical therapy following experimental traumatic brain injury

Pilar Hernandez Jimenez | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Pilar Hernandez Jimenez | Personalized Medicine | Women Researcher Award

Dr. Pilar Hernandez Jimenez, Hospital Universitario 12 de Octubre, Spain

Dr. María del Pilar Hernández Jiménez 🩺🔬 is a specialist in internal medicine with a focus on infectious diseases. She earned her M.D. from the Universidad de Alcalá (2011) and completed her MIR in Internal Medicine at HU 12 de Octubre (2013-2018). With expertise in HIV, tropical diseases, and antimicrobial resistance, she has contributed to multiple research projects, publishing 21 indexed articles (h-index 9). Currently, she is a Río Hortega researcher at Instituto de Salud Carlos III and a consultant at HU 12 de Octubre. Her doctoral thesis (2024) explores multidrug-resistant Pseudomonas aeruginosa.

Publication Profile

orcid

Education

Dr. Pilar Hernandez Jimenez 🎓 earned her Ph.D. in Health Sciences (2024) from Universidad Complutense de Madrid. She holds a Master’s in Infectious Diseases in Immunocompromised Patients 🦠 and has pursued multiple postgraduate specializations in infectious diseases, tropical medicine 🌍, and HIV 🏥. Her expertise spans critical areas of global health, focusing on combating infectious diseases and improving patient outcomes. With a strong academic foundation and extensive clinical knowledge, Dr. Hernandez Jimenez is dedicated to advancing research and medical practices in infectious disease management, contributing significantly to the field of immunocompromised patient care.

Experience

Dr. Pilar Hernandez Jimenez 🏥 currently serves at Instituto de Salud Carlos III and Hospital Universitario 12 de Octubre, where she plays a vital role in infectious disease research and hospital consultations. With extensive experience in leading studies on infectious diseases 🦠, she has contributed significantly to COVID-19 research 🦠, HIV studies 🏳️‍🌈, and infection management in immunocompromised patients 🤝. Her work bridges clinical practice and research, enhancing patient care and public health strategies. Through collaboration with top medical institutions, Dr. Hernandez Jimenez continues to make a meaningful impact on global health and infectious disease management.

International Exposure

Dr. Pilar Hernandez Jimenez 🌍 has gained extensive international exposure through Erasmus and MIR training in Spain 🇪🇸 and France 🇫🇷, enriching her expertise in infectious diseases. Her global collaborations extend to Brazil 🇧🇷, where she conducted research at Fundação de Medicina Tropical Doutor Heitor Vieira Dourado 🦠, contributing to advancements in tropical medicine and infectious disease management. These international experiences have allowed her to engage with diverse healthcare systems, collaborate with leading researchers, and enhance her medical practice on a global scale. Dr. Hernandez Jimenez continues to foster cross-border medical innovation and research excellence.

Research Focus

Dr. María del Pilar Hernández-Jiménez is a distinguished infectious disease researcher 🦠 specializing in prosthetic joint infections, multidrug-resistant bacteria, and antimicrobial treatments 💊. Her research focuses on periprosthetic infections, Pseudomonas aeruginosa, carbapenemase-producing Klebsiella pneumoniae, and infections in immunocompromised and transplant patients 🏥. She has contributed significantly to clinical microbiology, antimicrobial resistance, and infection control 📊. Dr. Hernández-Jiménez’s work extends to COVID-19-related infections and innovative treatments for latent tuberculosis in transplant recipients 🌍. Her extensive collaborations and impactful publications highlight her global influence in infectious disease research 🔬.

Publication Top Notes

Periprosthetic Infection of Transfibular Ankle Arthroplasties Managed with Implant Retention: Anatomical Limitations of Surgical Debridement

Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review

Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection

Enhancing screening adherence for strongyloides infection in latinx inpatients with COVID-19: a local protocol implementation study.

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[18F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
2-[18]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome